The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bairamova S.P.

Serbsky National Medical Research Center of Psychiatry and Narcology

Pavlova O.V.

Serbsky National Medical Research Center of Psychiatry and Narcology

Shport S.V.

Serbsky National Medical Research Center of Psychiatry and Narcology

Gurina O.I.

Serbsky National Medical Research Center of Psychiatry and Narcology

Pavlov K.A.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

The relationship of cytochrome P450 isoforms with the efficacy and safety of antipsychotic and antidepressant therapy

Authors:

Bairamova S.P., Pavlova O.V., Shport S.V., Gurina O.I., Pavlov K.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11): 40‑46

DOI: 10.17116/jnevro202312311140

Read: 4276 times

Download PDF (RU)
Contact the author
Table of contents

THE RELATIONSHIP OF CYTOCHROME P450 ISOFORMS WITH THE EFFICACY AND SAFETY OF ANTIPSYCHOTIC AND ANTIDEPRESSANT THERAPY
THE RELATIONSHIP OF CYTOCHROME P450 ISOFORMS WITH THE EFFICACY AND SAFETY OF ANTIPSYCHOTIC AND ANTIDEPRESSANT THERAPY

To cite this article:

Bairamova SP, Pavlova OV, Shport SV, Gurina OI, Pavlov KA. The relationship of cytochrome P450 isoforms with the efficacy and safety of antipsychotic and antidepressant therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11):40‑46. (In Russ.)
https://doi.org/10.17116/jnevro202312311140

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effect of poly­morphic variants of the HTR2A gene on the effe­ctiveness and safety of sertraline in patients with mixed anxiety-depressive diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):75-84
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Asso­ciations of poly­morphic variants of CYP2C19*2, *17 with effe­ctiveness and safety of sertraline in adolescents with a depressive episode and suicidal tendencies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):12-20
Search for risk factors for slowed intra-atrial conduction in patients with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):111-116
Transcranial electrostimulation as part of combination therapy for mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(1):37-44
Effi­cacy and safety of Cortexin as addi­tional therapy in patients with depressive diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(2):92-96
Neuropathic pain in chro­nic inflammatory demye­linating poly­neuropathies: analysis of 64 cases. Russian Journal of Pain. 2025;(2):45-53
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411
Effe­cts of corticosterone and anti­depressants fluoxetine and amitriptyline on the expression of neurotrophic factors in rat astrocytoma C6 cells. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(4-2):111-120
News in mole­cular biology. Digest of scientific publications. Issue 2. Labo­ratory Service. 2025;(4):5-7
Abstract:

Cytochrome P450 (CYP450) is the leading enzyme in the biotransformation of most psychotropic drugs. CYP450 gene polymorphisms determine a patient’s endophenotype with respect to the activity of enzymes of the family and affect the metabolism of prescribed antipsychotics and antidepressants. Categorizing patients by endophenotype during genotyping is likely to help simplify the selection of therapy in clinical practice. Co-prescribing drugs that may be inhibitors or inducers of CYP450 isoforms, in turn, may lead to adverse reactions or no effect of therapy. The article presents a compilation of known pharmacogenetic recommendations regarding the four major endophenotypes of metabolizers.

Keywords:

cytochrome P450
CYP450
CYP2D6
CYP3A4
pharmacogenetics
antipsychotics
antidepressants

Authors:

Bairamova S.P.

Serbsky National Medical Research Center of Psychiatry and Narcology

Pavlova O.V.

Serbsky National Medical Research Center of Psychiatry and Narcology

Shport S.V.

Serbsky National Medical Research Center of Psychiatry and Narcology

Gurina O.I.

Serbsky National Medical Research Center of Psychiatry and Narcology

Pavlov K.A.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Received:

23.12.2022

Accepted:

25.04.2023

Close metadata

References:

  1. Morozova AYu, Zubkov EA, Zorkina IaA, et al. Genetic aspects of schizophrenia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(6):126-132. (In Russ.). https://doi.org/10.17116/jnevro201711761126-132
  2. Arranz MJ, Salazar J, Hernández MH. Pharmacogenetics of antipsychotics: Clinical utility and implementation. Behav Brain Res. 2021;401:113058. https://doi.org/10.1016/j.bbr.2020.113058
  3. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 [published correction appears in Pharmacopsychiatry. 2018;51(1-02):e1]. Pharmacopsychiatry. 2018;51(1-02):9-62.  https://doi.org/10.1055/s-0043-116492
  4. Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2014;10(5):721-746.  https://doi.org/10.1517/17425255.2014.885504
  5. Soria-Chacartegui P, Villapalos-García G, Zubiaur P, Abad-Santos F, Koller D. Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. Front Pharmacol. 2021;12:711940. Published 2021 Jul 14.  https://doi.org/10.3389/fphar.2021.711940
  6. Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. Am J Psychiatry. 2018;175(5):463-470.  https://doi.org/10.1176/appi.ajp.2017.17050550
  7. Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry. 2019;6(5):418-426.  https://doi.org/10.1016/S2215-0366(19)30088-4
  8. Milosavljevic F, Bukvic N, Pavlovic Z, et al. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;78(3):270-280.  https://doi.org/10.1001/jamapsychiatry.2020.3643
  9. Thümmler S, Dor E, David R, et al. Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6. Front Psychiatry. 2018;9:2. Published 2018 Jan 24.  https://doi.org/10.3389/fpsyt.2018.00002
  10. Oshikoya KA, Neely KM, Carroll RJ, et al. CYP2D6 genotype and adverse events to risperidone in children and adolescents. Pediatr Res. 2019;85(5):602-606.  https://doi.org/10.1038/s41390-019-0305-z
  11. Ivashchenko DV, Yudelevich DA, Buromskaya NI, et al. CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes. Drug Metab Pers Ther. 2021;10.1515/dmdi-2021-0124. https://doi.org/10.1515/dmdi-2021-0124
  12. van Westrhenen R, Ingelman-Sundberg M. Editorial: From Trial and Error to Individualised Pharmacogenomics-Based Pharmacotherapy in Psychiatry. Front Pharmacol. 2021;12:725565. Published 2021 Sep 22.  https://doi.org/10.3389/fphar.2021.725565
  13. Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13(1):116-124.  https://doi.org/10.1111/cts.12692
  14. Carvalho Henriques B, Buchner A, Hu X, et al. Methodology for clinical genotyping of CYP2D6 and CYP2C19 [published correction appears in Transl Psychiatry. 2022;12(1):94]. Transl Psychiatry. 2021;11(1):596. Published 2021 Nov 22.  https://doi.org/10.1038/s41398-021-01717-9
  15. Yasukochi Y, Satta Y. Evolution of the CYP2D gene cluster in humans and four non-human primates. Genes Genet Syst. 2011;86(2):109-116.  https://doi.org/10.1266/ggs.86.109
  16. Carrascal-Laso L, Isidoro-García M, Ramos-Gallego I, Franco-Martín MA. Review: Influence of the CYP450 Genetic Variation on the Treatment of Psychotic Disorders. J Clin Med. 2021;10(18):4275. Published 2021 Sep 21.  https://doi.org/10.3390/jcm10184275
  17. Hoffmann MF, Preissner SC, Nickel J, et al. The Transformer database: biotransformation of xenobiotics. Nucleic Acids Res. 2014;42(Database issue):D1113-7.  https://doi.org/10.1093/nar/gkt1246
  18. Lisbeth P, Vincent H, Kristof M, et al. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol [published correction appears in Eur J Clin Pharmacol. 2016;72(2):175-84]. Eur J Clin Pharmacol. 2016;72(2):175-184.  https://doi.org/10.1007/s00228-015-1965-1
  19. Belmonte C, Ochoa D, Román M, et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2018;122(6):596-605.  https://doi.org/10.1111/bcpt.12960
  20. Dienstmann R, Patnaik A, Garcia-Carbonero R, et al. Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discov. 2015;5(6):598-609.  https://doi.org/10.1158/2159-8290.CD-14-1432
  21. Kiss Á, Menus Á, Tóth K, et al. Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure. Eur Arch Psychiatry Clin Neurosci. 2020;270(1):71-82.  https://doi.org/10.1007/s00406-018-0975-2
  22. Annotation of DPWG Guideline. Accessed December 12, 2022. https://www.pharmgkb.org
  23. Citrome L, Macher JP, Salazar DE, Mallikaarjun S, Boulton DW. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol. 2007;27(3):279-283.  https://doi.org/10.1097/jcp.0b013e318056f309
  24. de Leon J, Schoretsanitis G. CYP2D6 pharmacogenetics and risperidone: reflections after 25 years of research. Pharmacogenomics. 2020;21(16):1139-1144. https://doi.org/10.2217/pgs-2020-0115
  25. Kang RH, Jung SM, Kim KA, et al. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol. 2009;29(3):272-277.  https://doi.org/10.1097/JCP.0b013e3181a289e0
  26. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte — an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662-673.  https://doi.org/10.1038/clpt.2011.34
  27. van der Weide K, van der Weide J. The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients. J Clin Psychopharmacol. 2014;34(2):256-260.  https://doi.org/10.1097/JCP.0000000000000070
  28. Zubiaur P, Soria-Chacartegui P, Villapalos-García G, Gordillo-Perdomo JJ, Abad-Santos F. The pharmacogenetics of treatment with olanzapine. Pharmacogenomics. 2021;22(14):939-958.  https://doi.org/10.2217/pgs-2021-0051
  29. Fabbri C, Zohar J, Serretti A. Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:36-44.  https://doi.org/10.1016/j.pnpbp.2018.05.007
  30. Tansey KE, Guipponi M, Hu X, et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry. 2013;73(7):679-682.  https://doi.org/10.1016/j.biopsych.2012.10.030
  31. Fabbri C, Serretti A. Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies. Neurosci Lett. 2020;726:133651. https://doi.org/10.1016/j.neulet.2018.06.020
  32. Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015;98(2):127-134.  https://doi.org/10.1002/cpt.147
  33. Zhou SF, Zhou ZW, Yang LP, Cai JP. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-3675. https://doi.org/10.2174/092986709789057635
  34. Spigset O, Axelsson S, Norström A, Hägg S, Dahlqvist R. The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol. 2001;57(9):653-658.  https://doi.org/10.1007/s002280100373
  35. Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013;47(10):1330-1341. https://doi.org/10.1177/1060028013501994
  36. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005;33(2):262-270.  https://doi.org/10.1124/dmd.104.002428
  37. Chen G, Højer AM, Areberg J, Nomikos G. Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clin Pharmacokinet. 2018;57(6):673-686.  https://doi.org/10.1007/s40262-017-0612-7
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.